ClinicalTrials.gg
RecruitingNCT05952245Updated May 30, 2024

Instant Message-delivered Cognitive Behavioural Therapy for Insomnia (CBT-I)Stroke Caregivers

An interventional study of iCBTI-based EMI and Education-based EMI in Stroke, Insomnia and Depressive Symptoms, sponsored by The University of Hong Kong. Recruiting at 5 sites in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-30.

Sponsored by The University of Hong Kong · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Stroke by The University of Hong Kong — 4 open to participants now, 5 under way, none of them phase 3. Stroke · The University of Hong Kong.

Planned enrollment
6th of 15
138 · median 102
Started
2023
with 4 others
No phase
14 of 18
3 open now
Registered
16th of 18
by date

Among the 18 studies in Stroke by The University of Hong Kong, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2023, is one of 14 with no phase, and was the 16th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

4 of the 18 studies in Stroke by The University of Hong Kong are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Stroke by The University of Hong Kong, or all of them as a file.
02

Study summary

The proposed trial aims to assess the effectiveness of Cognitive-behavioural therapy for insomnia (CBT-I) based ecological momentary intervention (EMI) for reducing insomnia symptoms among stroke caregivers.

Read the detailed description

Existing studies reported that 40-95% of family caregivers had clinically significant insomnia symptoms including reduced total sleep duration, prolonged sleep onset latency, frequent night awakenings, and poor sleep efficiency and quality.

Cognitive-behavioural therapy for insomnia (CBT-I) has shown a large effect in reducing insomnia among adults. Innovative and interactive technologies, such as Internet-delivered CBT-I (iCBT-T), have therefore been incorporated into CBT-I, which was identified to have similar effects to that of traditional CBT-I.

In the proposed trial, screened stroke caregivers will be recruited from community centres, rehabilitation centres, and tertiary hospitals in HK. The intervention group will receive CBTI-based EMI through instant messaging applications as personalised and real-time psychological support led by nurses for 3 months. The control group will only receive stroke and brief sleep hygiene education with chat-based support on the topics.The primary outcomes are Sleep Condition Indicator (SCI) and Insomnia Severity Index (ISI) scores. Secondary outcomes will include sleep quality, depressive symptoms, anxiety symptoms, caregiver's burden, quality of life, and et al. A post-trial qualitative study will be conducted to understand the participants' experience of and compliance with the EMI.

03

Conditions studied

  • Stroke
  • Insomnia
  • Depressive Symptoms
  • Caregiver Burnout
  • Psychological Distress
  • Mobile Phone Use
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary family caregiver (Aged ≥18) of stroke survivor
  • Able to read and communicate in Chinese
  • Engaged caregiving roles for > 4 hours per day;
  • Able to use a smartphone messaging app (e.g., WhatsApp and WeChat)
  • SCI ≤ 21 scores (i.e., insomnia)

Exclusion criteria

Exclusion Criteria:

  • Has provided care for \<1 month prior to recruitment
  • Has a diagnosis of psychiatric disease or is currently taking psychotropic drugs
  • Currently taking medication to help with sleep
  • Currently participating in any type of psychological intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Receiving CBT-I based EMI messages.

    Behavioral: iCBTI-based EMI

  • Active comparator
    Control Group

    Receiving education-based EMI messages.

    Behavioral: Education-based EMI

Interventions

  • BehavioraliCBTI-based EMI

    Including brief iCBT-I for sleep support, stroke care education, and nurse-led real-time chat-based support messages, which were delivered according to participants' preferences (e.g., time and frequency).

  • BehavioralEducation-based EMI

    Stroke and brief sleep hygiene education with chat-based support on the topics.

06

What researchers measure

Primary outcomes

  1. Sleep Condition Indicator (SCI)

    An eight-item rating scale that was developed to screen for insomnia disorder based on DSM-5 criteria. Possible total score ranges from 0 to 32, with higher values indicative of better sleep.

    Time frame: 24 weeks

  2. Insomnia Severity Index (ISI)

    A 7-item scale with scoring ranging from 0-28, a higher score indicate more severe insomnia symptoms

    Time frame: 24 weeks

Secondary outcomes

  1. Sleep quality (Pittsburgh Sleep Quality Index [PSQI])

    A 19-item scale ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality

    Time frame: 24 weeks

  2. Depressive symptoms (Patient Health Questionnaire-9 [PHQ-9]):

    A 9-item scale with score ranging from 0 to 27, higher scores indicate higher severity of depressive symptom

    Time frame: 24 weeks

  3. Anxiety symptoms (Generalized Anxiety Disorder-7 [GAD-7])

    A 7-item scale with score ranging from 0 to 21, higher scores indicate higher severity of anxiety symptom

    Time frame: 24 weeks

  4. Caregiver's burden (Zarit Burden Interview [ZBI-4])

    A 4-item scale with score ranging from 0 to 16, higher scores indicate higher severity of caregiving burden

    Time frame: 24 weeks

  5. Quality of life (EuroQol 5-dimension 5-level questionnaire [EQ-5D-5L])

    The EQ-5D-5L assesses five health dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each rated on five levels of severity, with scores ranging from -0.864 to 1, where higher scores indicate better quality of life. Additionally, it includes a visual analogue scale (VAS), ranging from 0 (the worst health imaginable) to 100 (the best health imaginable).

    Time frame: 24 weeks

  6. Positive experiences from caregiving (Positive Aspect of Caregiving [PAC])

    An 11-item scale with scores ranging from 0 to 44. A higher score indicates a more positive caregiving experience.

    Time frame: 24 weeks

  7. Caregiving self-efficacy (Caregiving Self-Efficacy Scale [CSES-8])

    An 8-item scale with scores ranging from 1 to 10, with higher scores indicating higher self-efficacy.

    Time frame: 24 weeks

  8. Sleep parameters (Consensus Sleep Diary Core Version)

    The Consensus Sleep Diary Core Version will be used to collect sleep parameters (e.g., sleep efficiency and total sleep time).

    Time frame: 24 weeks

  9. Dysfunctional Beliefs and attitudes about Sleep (Dysfunctional Beliefs and attitudes about Sleep [DBAS])

    A 16-item scale with scores ranging from 0 to 160, with higher scores indicating greater dysfunctional beliefs about sleep.

    Time frame: 24 weeks

  10. Sleep hygiene statue (Sleep Hygiene Index [SHI])

    A 13-item scale with ratings from 0 to 52, where higher scores indicate poorer sleep hygiene status.

    Time frame: 24 weeks

  11. Sleep-related behavior (Chinese short-form of the sleep-related behavior questionnaire [SRBQ-SF])

    A 23-item scale with scores ranging from 0 to 92. A higher score indicates more sleep-related safety behaviors.

    Time frame: 24 weeks

  12. State of sleep effort (Glasgow Sleep Effort Scale [GSES])

    A 7-item scale with scores ranging from 0 to 14, where higher scores indicate greater effort to sleep over the past week.

    Time frame: 24 weeks

  13. Sleep-related quality of life (Glasgow Sleep Impact Index [GSII])

    The primary measureable outcomes for the GSII reflect VAS scores (0-100; with lower scores reflecting negative impact) for each of the three specified ranks, capturing impairment in the past two weeks. GSII reflect VAS scores (0-100; with lower scores reflecting negative impact) for each of the three

    Time frame: 24 weeks

  14. Feedback on iCBT-I intervention

    Feedback on the sleep support programme will be collected, focusing on various aspects such as perceived usefulness and willingness to recommend the program. Each aspect will be evaluated using a 5-point Likert scale, where higher scores indicate more positive evaluations.

    Time frame: 24 weeks

  15. Adverse events

    Feedback on adverse events related to the iCBT-I intervention, such as fatigue, will be collected.

    Time frame: 24 weeks

07

Study locations

5 of 5 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2024, 12 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 12 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Jul 19, 2023
StartActual
Dec 1, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Mar 2025
Last update
May 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05952245
Responsible party
Sponsor
First posted
Jul 19, 2023
Start date
Dec 1, 2023
Primary completion
Dec 2024 (estimated)
Completion
Mar 2025 (estimated)
Last update
May 30, 2024

Study contacts

Jung Jae LEE
Contact
leejay@hku.hk
+852 3917 6971

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion